Why Lam Research Shares Are Moving Higher Tuesday

Lam Research said its board approved a new share repurchase program of up to $10 billion of the company's common stock. The new buyback supplements the remaining balances from any prior authorizations. Lam Research also plans to enact a 10-for-1 split of its common stock.

Lam Research Corp (NASDAQ:LRCX) stock is trading higher Tuesday after the company announced a buyback authorization and stock split.

What Happened: Lam Research said its board approved a new share repurchase program of up to $10 billion of the company’s common stock. The new buyback supplements the remaining balances from any prior authorizations. 

Repurchases may be conducted through public and private transactions, including the use of derivative contracts and structured share repurchase agreements. Lam Research noted that the buyback program has no expiration date and can be paused or terminated at any time.

“The share repurchase authorization announced today will execute over an indeterminate period of time and is consistent with our plan to return 75% to 100% of free cash flow to stockholders in the form of dividends and share buybacks,” said Doug Bettinger, executive vice president and CFO of Lam Research.

“Furthermore, the stock split announced today will enable a larger proportion of Lam’s worldwide employee base to participate in the company’s employee stock plans.”

Lam Research plans to enact a 10-for-1 split of its common stock. The stock split is anticipated to take effect following the market close on Oct. 2 for shareholders of record at that time. Lam Research’s common stock will begin trading on a post-split basis at the market open on Oct. 3.

Related Link: What 15 Analyst Ratings Have To Say About Ecolab

LRCX Price Action: Lam Research stock was up 2.12% at $962 at the time of publication, according to Benzinga Pro.

Image: Courtesy of Lam Research.

Total
0
Shares
Related Posts
Read More

What’s Going On With Weed Stocks Aurora Cannabis And Canopy Growth?

Aurora Cannabis, Inc. and Canopy Growth Corporation shares are trading lower Tuesday in sympathy with Tilray Brands which fell after reporting worse-than-expected third-quarter results. Tilray reported quarterly sales of $188.34 million which, missing the analyst consensus estimate of $198.5 million by 5.12 percent%. The company also said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.

ACB

Read More

Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday

Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to Overweight. Regeneron Pharmaceuticals shares rose 0.9% to $714.99 in pre-market trading.

ALGN